Adequately nourished AML patients have survival advantageNovember 3, 2017Leukemia, Myelodysplasia, Transplantation
Idelalisib efficacy against CLL tarnished by toxicityOctober 28, 2017Leukemia, Myelodysplasia, Transplantation
Deep remission or long-term control? Choice is key in early CLLOctober 27, 2017Leukemia, Myelodysplasia, Transplantation
‘Year of AML’ just the beginning, expert saysOctober 26, 2017Leukemia, Myelodysplasia, Transplantation
AML patients overestimate treatment risk and chance of cureOctober 25, 2017Patient & Survivor CareLeukemia, Myelodysplasia, Transplantation
FDA approves second CAR-T therapyOctober 19, 2017Leukemia, Myelodysplasia, TransplantationImmuno-oncology
Cascade of costs could push new gene therapy above $1 million per patientOctober 17, 2017Immuno-oncologyLeukemia, Myelodysplasia, Transplantation
Minimal residual disease measures not yet impactful for AML patientsOctober 12, 2017Leukemia, Myelodysplasia, Transplantation
ALL therapies grow, so do the complexities of choosing the order of treatmentsOctober 9, 2017Leukemia, Myelodysplasia, Transplantation
Plerixafor doesn’t overcome HPC failure in R-hyperCVAD for mantle cell lymphomaSeptember 10, 2017Leukemia, Myelodysplasia, Transplantation
CB-5083 showed significant activity against B-ALLSeptember 9, 2017Leukemia, Myelodysplasia, Transplantation
New AML approvals changing the treatment landscapeSeptember 8, 2017Leukemia, Myelodysplasia, Transplantation
FDA reapproves gemtuzumab ozogamicin for CD33-positive AML treatmentSeptember 1, 2017Leukemia, Myelodysplasia, TransplantationPediatrics
FDA approves first gene therapy – tisagenlecleucel for ALLAugust 30, 2017Leukemia, Myelodysplasia, TransplantationPediatricsImmuno-oncology
